[MOL] Treatment for Chronic Melogenous Leukemia and acute and chronic Le [12772] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] Treatment for Chronic Melogenous Leukemia and acute and chronic Leukemia



More information flowing on this treatment for other major diseases.
Take care all and have a great day.

God Bless
marty auslander


Hycamtin As Combination Therapy Shows Promising Results in MDS and CMML

In this phase II study, 35 patients with either MDS (n=21) or CMML
(n=14)
received Hycamtin 1.25 mg/m2 intravenously over 24 hours daily for five
days
and high dose ara-C 1 g/m2 over two hours daily for five days. 
Twenty-two
patients (63 percent) achieved a complete response, 80 percent of which
did
so after only one course of therapy.  A complete response was defined as
bone
marrow with 5 percent or fewer blasts (immature marrow cells) and
normalization of the hemoglobin, platelets and white blood cells.  In
addition, patients who achieved a complete response no longer required
blood
transfusions, and those with pre-existing chromosomal abnormalities
showed
disappearance of these abnormalities.

Investigators also compared these results with those from another study
involving FAI-G ATRA [fludarabine, ara-C, idarubicin with or without
G-CSF
(granulocyte-colony stimulating factor) and ATRA (all-trans retinoic
acid)],
anothor investigational therapy for the treatment of MDS patients.  The
preliminary analysis showed that FAI-G ATRA-treated patients achieved a
complete response rate of 46 percent.

"Prior to this study, patients with CMML or MDS who were treated with
high-dose ara-C as single-agent therapy showed response rates of only 20
to
30 percent.  By combining Hycamtin with ara-C, we have seen a dramatic
increase in response rates among these patients while maintaining an
acceptable side effect profile," said Dr. Beran.  "This study is also
important because we have seen high remission rates and low
treatment-related
mortality among patients treated with this combination therapy.  In
contrast,
although other drugs in combination with high-dose ara-C have also
increased
remission rates, they have increased treatment-related mortality,
particularly in elderly patients who represent a majority of cases."

Hycamtin was generally well-tolerated.  The main side effects
experienced
were fever and neutropenia (low white blood cell count) with or without
infection.  Severe mucositis and gastrointestinal problems occurred in
only
three percent of patients.


Previous Study Demonstrates Hycamtin's Activity As Single-Agent Therapy

This study presented today at ASH was initiated after a previous study
conducted at M.D. Anderson Cancer Center showed that patients with MDS
and
CMML who were treated with Hycamtin as single-agent therapy achieved a
30
percent complete response rate.  In comparison, currently-used
single-agent
therapies have traditionally achieved complete response rates of only
10-15
percent.  Based on the results from both of these studies, additional
clinical trials are underway involving the use of Hycamtin as
single-agent
therapy and in combination with other drugs for the treatment of chronic
myelogenous leukemia and acute and chronic leukemia.
------------------------------------------------------------------------
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------